Phrontline Biopharma (Hangzhou) Co. Ltd. has prepared and tested bispecific antibody-drug conjugates (bsADCs) comprising a bispecific antibody targeting B7 homolog 3 (B7-H3; CD276) and EGFR (HER1; erbB1) linked to a cytotoxic drug. They are described as potentially useful for the treatment of cancer.
Shanghai Allink Biotherapeutics Co. Ltd. has discovered new bispecific antibody-drug conjugates comprising a bispecific monoclonal antibody linked to a cytotoxic drug potentially useful for the treatment of cancer.
Foghorn Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding agent coupled to a histone acetyltransferase p300 (EP300)-targeting moiety. As such, they are described as EP300 degradation inducers potentially useful for the treatment of cancer.
Mesothelin (MSLN) is a highly expressed protein in several cancer types but with limited expression in normal tissues. Simcere Pharmaceutical Co. Ltd. has presented preclinical data on the characterization of SCR-A019, an antibody-drug conjugate (ADC) carrying a topoisomerase 1 inhibitor payload and an antibody that binds to membrane Mesothelin (MSLN) over soluble MSLN and has shown robust antitumor efficacy in several cell-derived xenograft models.
Pheast Therapeutics Inc. has presented preclinical data on PHST-677, a novel bispecific antibody-drug conjugate (ADC) targeting E-cadherin (CDH1) and Nectin-4.
Far beyond indications like breast cancer, there are sex differences in incidence across a broad range of tumor types. Particularly in glioblastoma, there is a clear male-biased incidence compared to females. The mechanisms that drive this difference are not well understood, buy may include an androgen-related immune response. Recent evidence suggests a key role for androgens in antitumoral immunity and their impact on the response to immune checkpoint inhibitor therapy.
Metis Techbio Co. Ltd. is seeking a potential HK$2.11 billion (US$270 million) raise through a stock sale May 13, marking the largest biotech raise on the Hong Kong Stock Exchange this year to date. Hangzhou, China-based Metis is an AI-based nanoparticle drug formulation and delivery-focused company. Synthetic lethality-based cancer drugmaker Impact Therapeutics Inc., of Shanghai, plans to debut on the same day with a US$117 million IPO.
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early development programs in the fields of oncology, hematology and immunology. Shanghai-based Hengrui will hold exclusive rights in mainland China, Hong Kong and Macau, while Princeton, N.J.-based BMS will hold exclusive rights in the rest of the world. The deal includes four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five assets that the two companies will jointly discover and develop.
Rigel Pharmaceuticals Inc. CEO Raul Rodriguez said breast cancer therapy Veppanu (vepdegestrant) could become his firm’s “largest product with the current label,” and other opportunities with the drug are lined up behind, albeit “still a bit early.”
RSS
